Serum Life Science Europe
Private Company
Funding information not available
Overview
Serum Life Science Europe GmbH is a specialized consultancy and service provider for biopharmaceutical development, with deep expertise in vaccines and biologics. Originally founded as Vakzine Projekt Management GmbH with German federal support, the company now operates as an independent entity majority-owned by the Serum Institute of India (SIIPL). SLS Europe generates revenue through client services while advancing its own pipeline of three main clinical-stage assets, including a novel tuberculosis vaccine candidate.
Technology Platform
Integrated consultancy and project management service platform for biopharmaceutical development; expertise in recombinant live-attenuated vaccine engineering (for proprietary assets).
Opportunities
Risk Factors
Competitive Landscape
In consultancy services, SLS Europe competes with global CROs (IQVIA, PPD) and niche regulatory consultancies. For its TB vaccine, it competes with other late-stage candidates from GSK (MTBVAC) and the Immune Response BioPharma/Aeras collaboration. In bladder cancer immunotherapy, it faces competition from established instillations and newer gene therapies.